* Intra-Cellular Therapies Inc is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2024
* The New York City-based company is expected to report a 48.3% increase in revenue to $141.358 million from $95.31 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Intra-Cellular Therapies Inc is for a loss of 32 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 2.4% in the last three months.
* Wall Street's median 12-month price target for Intra-Cellular Therapies Inc is $91.00, above its last closing price of $72.30.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.44 -0.44 -0.30 Beat 32.2
Sep. 30 2023 -0.56 -0.57 -0.25 Beat 55.8
Jun. 30 2023 -0.59 -0.59 -0.45 Beat 23.8
Mar. 31 2023 -0.59 -0.61 -0.46 Beat 24.1
Dec. -0.63 -0.59 -0.45 Beat 24
31 2022
Sep. 30 2022 -0.82 -0.81 -0.57 Beat 30
Jan. 1 0001 -0.73 -0.76 -0.92 Missed -21
Mar. 31 2022 -0.97 -0.92 -0.78 Beat 15.3
This summary was machine generated April 30 at 14:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments